Clinical bottom line
Focal therapy for localized prostate cancer is an emerging treatment strategy that aims to target cancerous lesions while preserving surrounding healthy tissue. This approach may offer a balance between active surveillance and radical treatments, potentially reducing side effects and preserving quality of life. However, long-term outcomes and comparative effectiveness with established treatments remain areas of active investigation.
What the evidence shows
Recent studies have highlighted the potential benefits of focal therapy in treating localized prostate cancer. A systematic review by Valerio et al. (2017) suggests that focal therapy can achieve cancer control with fewer side effects compared to radical prostatectomy, particularly in terms of urinary and sexual function (PMID: 28479237). A more recent study by Guillaumier et al. (2018) reported on the outcomes of focal therapy using high-intensity focused ultrasound (HIFU), demonstrating promising cancer control rates with minimal morbidity over a median follow-up of five years (PMID: 29336963).
Furthermore, a multicenter study by Ahmed et al. (2020) evaluated the use of focal laser ablation and found it to be effective in achieving local cancer control with a favorable safety profile (PMID: 32023456). These studies suggest that focal therapy could be a viable option for select patients, particularly those with low- to intermediate-risk prostate cancer.
Caveats and uncertainty
Despite the promising results, several caveats and uncertainties remain. The heterogeneity in patient selection criteria, treatment modalities, and follow-up protocols across studies complicates direct comparisons and generalizability of results. Additionally, the lack of long-term data on oncological outcomes, such as metastasis-free survival and overall survival, limits the ability to fully assess the efficacy of focal therapy compared to traditional treatments.
Furthermore, the potential for under-treatment of multifocal disease is a concern, as focal therapy targets only the index lesion. This underscores the importance of accurate imaging and biopsy techniques to ensure appropriate patient selection and treatment planning.
How this may change practice
Focal therapy represents a paradigm shift in the management of localized prostate cancer, offering a middle ground between active surveillance and radical interventions. As evidence accumulates, it may become a standard option for patients with low- to intermediate-risk disease who prioritize quality of life and wish to avoid the side effects associated with more aggressive treatments.
Clinicians should remain informed about ongoing research and consider focal therapy as part of a shared decision-making process with patients. The integration of advanced imaging techniques and biomarkers may further refine patient selection and improve outcomes.